Vaxart Newsroom

B.Riley Financial Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $2.5

Moomoo NewsNov 19, 2024 03:43 ET

Vaxart's Promising Advancements in Oral Vaccine Development and Norovirus Program Drive Buy Rating

TipRanksNov 18, 2024 19:56 ET

Oppenheimer Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 14, 2024 08:31 ET

Vaxart (VXRT) Receives a Buy From Oppenheimer

TipRanksNov 14, 2024 08:00 ET

Oppenheimer Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsOct 2, 2024 08:31 ET

Oppenheimer Sticks to Their Buy Rating for Vaxart (VXRT)

TipRanksOct 2, 2024 07:37 ET

B.Riley Financial Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $2.5

Moomoo NewsAug 16, 2024 08:31 ET

Oppenheimer Initiates Vaxart at Outperform With $4 Price Target

MT NewswiresAug 15, 2024 07:25 ET

Vaxart Analyst Ratings

BenzingaAug 15, 2024 05:32 ET

Buy Rating Affirmed for Vaxart Amidst Promising Norovirus Vaccine Developments and Market Opportunity

TipRanksJul 9, 2024 07:29 ET

B. Riley Raises Price Target on Vaxart to $2.50 From $2, Maintains Buy Rating

MT NewswiresJun 14, 2024 07:42 ET

Vaxart Analyst Ratings

BenzingaJan 31, 2024 09:46 ET

Analysts' Top Healthcare Picks: Vaxart (VXRT), Palisade Bio (PALI)

TipRanksJan 31, 2024 07:40 ET

Analyst Holds Vaxart Stock Rating Amid Positive Clinical Trials and Robust Vaccine Development Prospects

TipRanksNov 7, 2023 10:15 ET

Vaxart (VXRT) Receives a Buy From Cantor Fitzgerald

TipRanksSep 10, 2023 14:25 ET

B.Riley Financial Remains a Hold on Vaxart (VXRT)

TipRanksSep 7, 2023 14:45 ET

Cantor Fitzgerald Reiterates Overweight on Vaxart, Maintains $4 Price Target

BenzingaSep 7, 2023 09:21 ET

Vaxart Analyst Ratings

BenzingaSep 7, 2023 09:21 ET

Cantor Fitzgerald Maintains Overweight on Vaxart, Lowers Price Target to $4

BenzingaAug 7, 2023 09:07 ET

Vaxart Analyst Ratings

BenzingaAug 7, 2023 09:02 ET